Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Agilent acquires...

    Agilent acquires Luxcel Biosciences

    Written by Ruby Khatun Khatun Published On 2018-01-12T09:45:15+05:30  |  Updated On 12 Jan 2018 9:45 AM IST
    Agilent acquires Luxcel Biosciences

    Agilent Technologies Inc. announced it has acquired Cork, Ireland-based Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits.


    This acquisition expands Agilent's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers.


    "Technological advancements allowing researchers to examine cell health and function kinetically and in real-time are driving global demand for complete cell analysis solutions," said Todd Christian, General Manager of Agilent's Cell Analysis Division.


    "Luxcel's assay kits are optimized for standard fluorescent plate readers for broad customer application helping to address this growing demand."


    Luxcel is developing a portfolio of in vitro cell-based assay kits and solutions targeting cell metabolism, drug safety, and toxicity, as well as hypoxia and oxidative stress for a variety of life science customers from research institutions to pharmaceutical companies.


    Scientists use this technology to understand the role of cell metabolism across a variety of important research areas including cancer, metabolic disorders, cardiovascular disease, immunology, and infectious disease.


    Agilent entered the cell analysis market in 2015 with the acquisition of Seahorse Bioscience, a leader in providing specialized instruments and live-cell, kinetic assays. "Luxcel is highly complementary to our Seahorse offerings," said Christian. "With this acquisition, we further extend our leadership in live-cell, kinetic assays accelerating our expansion into pharmaceutical and biopharma discovery and in vitro toxicology screening applications."


    "We are a young and motivated group," said Richard Fernandes, CEO of Luxcel. "When Agilent approached us, it was clear to me that we have a shared passion for innovation designed to enable and support customers. Together, we have the potential to accelerate new product introductions by leveraging Agilent's R&D and global commercial infrastructures with our unique biosensor chemistries and assay development expertise."


    Founded in 2002 by Richard Fernandes and Dmitri Papkovsky as a spin-out company from University College Cork and a member of the High Potential Start-Up program at Enterprise Ireland, Luxcel has 12 employees and is headquartered in Cork, Ireland.


    The Luxcel team will remain in Cork and form a dedicated sensor chemistries and bioassay solutions group within Agilent's Cell Analysis Division. Financial terms of the deal are not being disclosed.

    AcquiresAcquisitionAgilentAgilent Technologies Incfluorescent plate readersin vitro cell assay kitsLuxcel BiosciencesRichard FernandesTodd Christian
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok